Product Development And License Agreement Sample Contracts

Share Cite Term
Link

Embed (HTML)
Product Development and License Agreement (November 2nd, 2010)
CONFIDENTIAL TREATMENT REQUESTED: Portions of This Exhibit Have Been Redacted Pursuant to a Request for Confidential Treatment Under Rule 24b-2 of the General Rules and Regulations Under the Securities Exchange Act of 1934, as Amended. Such Redacted Portions Have Been Replaced With {***} in This Exhibit. An Unredacted Version of This Document Has Been Filed Separately With the Securities and Exchange Commission Along With the Request for Confidential Treatment. First Amendment to the Product Development and License Agreement (February 26th, 2010)

Ghent University, public institution with legal personality, having its administrative offices in Belgium, B-9000 Gent, Sint-Pietersnieuwstraat 25 and duly represented by Prof. dr. Luc Moens, vice-rector (hereinafter referred to as University)

CONFIDENTIAL TREATMENT REQUESTED: Portions of This Exhibit Have Been Redacted Pursuant to a Request for Confidential Treatment Under Rule 24b-2 of the General Rules and Regulations Under the Securities Exchange Act of 1934, as Amended. Such Redacted Portions Have Been Replaced With {***} in This Exhibit. An Unredacted Version of This Document Has Been Filed Separately With the Securities and Exchange Commission Along With the Request for Confidential Treatment. PRODUCT DEVELOPMENT and LICENSE AGREEMENT (Diltiazem Bead Tablets) (February 26th, 2010)

BIOVAIL LABORATORIES INCORPORATED a Barbados corporation incorporated under the International Business Companies Act, 1991-24, whose head office is

Shire Ltd – Amendment to Product Development and License Agreement (May 7th, 2009)

This Amendment to the Product Development and License Agreement, effective as of February 24, 2009, is by and between Shire LLC, Shire Biopharmaceuticals Holdings (formerly known as Shire plc) (collectively "Shire") and Duramed Pharmaceuticals, Inc. ("Duramed"). Shire and Duramed are referred to together as the "Parties".

AMEDICA Corp – Product Development and License Agreement (July 18th, 2007)

THIS PRODUCT DEVELOPMENT AND LICENSE AGREEMENT (Agreement) is made and entered into this 20th day of December, 2006 (Effective Date), by and between AMEDICA CORPORATION, having its principal offices at 615 Arapeen Drive, Salt Lake City, Utah 84108 (AMEDICA), and DYTECH CORPORATION LTD, having its principal offices at Stopes Road, Stannington, Sheffield, S6 6BW England (DYTECH).

AMEDICA Corp – Product Development and License Agreement (June 27th, 2007)

THIS PRODUCT DEVELOPMENT AND LICENSE AGREEMENT (Agreement) is made and entered into this 20th day of December, 2006 (Effective Date), by and between AMEDICA CORPORATION, having its principal offices at 615 Arapeen Drive, Salt Lake City, Utah 84108 (AMEDICA), and DYTECH CORPORATION LTD, having its principal offices at Stopes Road, Stannington, Sheffield, S6 6BW England (DYTECH).

Nastech Pharmaceutical Company, Inc. – First Amendment Dated as of December 4, 2006 to Product Development and License Agreement by and Between Nastech Pharmaceutical Company Inc. And Procter & Gamble Pharmaceuticals, Inc. Dated as of January 27, 2006 (March 7th, 2007)

This First Amendment to the Product Development and License Agreement (the First Amendment) is entered into as of December 4, 2006 by and between PROCTER & GAMBLE PHARMACEUTICALS, INC., a corporation organized under the laws of Ohio (P&G), and NASTECH PHARMACEUTICAL COMPANY INC., a corporation organized under the laws of Delaware (Nastech), as an amendment to the Product Development and License Agreement (the Agreement) entered into as of January 27, 2006 by and between P&G and Nastech. All capitalized terms used herein shall have the meanings given in the Agreement.

Product Development and License Agreement by and Between Shire Llc and Duramed Pharmaceuticals, Inc. Dated as of August 14, 2006 (November 9th, 2006)

This PRODUCT DEVELOPMENT AND LICENSE AGREEMENT (the Agreement) is dated as of August 14, 2006 by and among SHIRE LLC, a Kentucky limited liability company having a principal place of business at 9200 Brookfield Court, Florence, Kentucky 41042 (together with its Affiliates, Shire), SHIRE plc, a British public limited company having a principal place of business at Hampshire International Business Park, Chineham, Basingstoke, England RG24 8EP, solely for purposes of the provisions of Section 15.10 of this Agreement, and DURAMED PHARMACEUTICALS, INC., a Delaware corporation having a place of business at 400 Chestnut Ridge Road, Woodcliff Lake, NJ 07677 (Duramed). Shire and Duramed are sometimes referred to herein individually as a Party and together as the Parties.

Shire Ltd – Product Development and License Agreement by and Between Shire Llc and Duramed Pharmaceuticals, Inc. Dated as of August 14, 2006 (November 7th, 2006)

This PRODUCT DEVELOPMENT AND LICENSE AGREEMENT (the Agreement) is dated as of August 14, 2006 by and among SHIRE LLC, a Kentucky limited liability company having a principal place of business at 9200 Brookfield Court, Florence, Kentucky 41042 (together with its Affiliates, Shire), SHIRE plc, a British public limited company having a principal place of business at Hampshire International Business Park, Chineham, Basingstoke, England RG24 8EP, solely for purposes of the provisions of Section 15.10 of this Agreement, and DURAMED PHARMACEUTICALS, INC., a Delaware corporation having a place of business at 400 Chestnut Ridge Road, Woodcliff Lake, NJ 07677 (Duramed). Shire and Duramed are sometimes referred to herein individually as a Party and together as the Parties.

Nastech Pharmaceutical Company, Inc. – Product Development and License Agreement by and Between Nastech Pharmaceutical Company Inc. And Procter & Gamble Pharmaceuticals, Inc. Dated as of January 27, 2006 (February 2nd, 2006)

This Product Development and License Agreement (the Agreement) is entered into as of January 27, 2006 by and between PROCTER & GAMBLE PHARMACEUTICALS, INC., a corporation organized under the laws of Ohio (P&G), and NASTECH PHARMACEUTICAL COMPANY INC., a corporation organized under the laws of Delaware (Nastech).

Elite Pharmaceuticals, Inc. – Contract (September 6th, 2005)

CONFIDENTIAL TREATMENT REQUEST [ * ] INDICATES INFORMATION THAT HAS BEEN OMITTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST AND THIS INFORMATION HAS BEEN FILED UNDER SEPARATE COVER WITH THE COMMISSION PRODUCT DEVELOPMENT AND LICENSE AGREEMENT THIS PRODUCT DEVELOPMENT AND LICENSE AGREEMENT (together with all exhibits and schedules, the "Agreement"), dated as of June 22, 2005 ( the "Effective Date") by and between ELITE LABORATORIES, INC., a corporation organized and existing under the laws of Delaware, and having its principal place of business at 165 Ludlow Avenue, Northvale, NJ 07647 ("ELITE") and PLIVA, INC., a corporation organized and existing under the laws of New Jersey, and having its principal place of busin

Elite Pharmaceuticals, Inc. – Contract (June 28th, 2005)

CONFIDENTIAL TREATMENT REDACTED VERSION PRODUCT DEVELOPMENT AND LICENSE AGREEMENT THIS PRODUCT DEVELOPMENT AND LICENSE AGREEMENT (together with all exhibits and schedules, the "Agreement"), dated as of June 22, 2005 ( the "Effective Date") by and between ELITE LABORATORIES, INC., a corporation organized and existing under the laws of Delaware, and having its principal place of business at 165 Ludlow Avenue, Northvale, NJ 07647 ("ELITE") and PLIVA, INC., a corporation organized and existing under the laws of New Jersey, and having its principal place of business at 72 Eagle Rock Avenue, East Hanover, NJ 07936 ("PLIVA"). RECITALS: PLIVA is engaged in the development, manufacturing, marketing and distribution of generic pharmaceutical products in the Territory (as defined below) and possesses qualified marketing and distribution systems

Coley Pharmaceutical Group – Amendment #1 to Amended and Restated Product Development and License Agreement Between Aventis Pharmaceuticals Inc. And Coley Pharmaceutical Group, Inc. (April 20th, 2005)

This Amendment #1 to the Amended and Restated Product Development and License Agreement (Amendment #1), is made as of August 6, 2003 (the Effective Date), by and between COLEY PHARMACEUTICAL GROUP, INC., a Delaware corporation having a place of business at Wellesley Gateway, 93 Worcester Street, Suite 101, Wellesley, Massachusetts 02481 (Coley), and AVENTIS PHARMACEUTICALS INC., a Delaware corporation having a place of business at 200 Crossing Boulevard, P.O. Box 6890, Bridgewater, New Jersey 08807 (Aventis) (each individually a Party and collectively the Parties).

Coley Pharmaceutical Group – AMENDED.AND Restated Product Development and License Agreement (April 20th, 2005)

THIS AMENDED AND RESTATED PRODUCT DEVELOPMENT AND LICENSE AGREEMENT (this Agreement) is made as of December 21, 2001, by and between COLEY PHARMACEUTICAL GROUP, INC., a Delaware corporation having a place of business at Wellesley Gateway, 93 Worcester Street, Suite 101, Wellesley, Massachusetts 02481 (Coley), and AVENTIS PHARMACEUTICALS INC., a Delaware corporation having a place of business at Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807 (Aventis) (each individually a Party and collectively the Parties).

Synovics Pharmaceuticals Inc. – Product Development and License Agreement (September 15th, 2004)

This license agreement (the Agreement) dated as of June 16, 2004 (the Effective Date) is entered into by and between Nostrum Pharmaceuticals, Inc. (Nostrum), a Delaware corporation, and Bionutrics, Inc. (Bionutrics), a Nevada corporation.